{"id":"indomethacin-0-5-eyedrops","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Corneal erosion or keratitis"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3989410","moleculeType":"Small molecule","molecularWeight":"433.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a topical NSAID eyedrop, indomethacin blocks COX-1 and COX-2 enzymes, thereby decreasing production of inflammatory prostaglandins in ocular tissues. This reduces inflammation, pain, and potentially other prostaglandin-mediated effects in the anterior segment of the eye. The 0.5% formulation delivers the drug directly to ocular tissues with minimal systemic absorption.","oneSentence":"Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:52.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative ocular inflammation and pain following cataract surgery"},{"name":"Seasonal allergic conjunctivitis"},{"name":"Corneal refractive surgery-related inflammation"}]},"trialDetails":[{"nctId":"NCT06539637","phase":"EARLY_PHASE1","title":"Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%","status":"RECRUITING","sponsor":"DHS Consulting","startDate":"2023-09-01","conditions":"Cataract","enrollment":20},{"nctId":"NCT06498440","phase":"PHASE4","title":"Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT","status":"NOT_YET_RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2024-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension, Postoperative Inflammation","enrollment":126},{"nctId":"NCT00981435","phase":"PHASE4","title":"Steroids After Laser Trabeculoplasty for Glaucoma","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-09","conditions":"Glaucoma","enrollment":97},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT01769352","phase":"PHASE2, PHASE3","title":"Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":"Post-surgical Cystoid Macular Edema (PSCME)","enrollment":42},{"nctId":"NCT03261635","phase":"PHASE4","title":"Ranibizumab Plus Indomethacin","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2016-01-07","conditions":"Macular Edema","enrollment":58},{"nctId":"NCT02752646","phase":"NA","title":"Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%","status":"COMPLETED","sponsor":"MDbackline, LLC","startDate":"2016-04","conditions":"Cataract","enrollment":200},{"nctId":"NCT00405730","phase":"PHASE3","title":"Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-11","conditions":"Cataracts","enrollment":227},{"nctId":"NCT00478036","phase":"NA","title":"Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":"Open Angle Glaucoma","enrollment":31},{"nctId":"NCT00485108","phase":"NA","title":"Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty","status":"COMPLETED","sponsor":"Queen's University","startDate":"2007-01","conditions":"Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma","enrollment":120},{"nctId":"NCT02361645","phase":"PHASE3","title":"NSAIDs and PGE2 Levels in Vitrectomy Patients","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2014-03","conditions":"Vitreous Inflammation","enrollment":70},{"nctId":"NCT00904904","phase":"PHASE4","title":"Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-04","conditions":"Cataract, Inflammation","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Indomethacin 0.5% eyedrops","genericName":"Indomethacin 0.5% eyedrops","companyName":"Università degli Studi di Brescia","companyId":"universit-degli-studi-di-brescia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. Used for Postoperative ocular inflammation and pain following cataract surgery, Seasonal allergic conjunctivitis, Corneal refractive surgery-related inflammation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}